Table 2 Univariate and multivariate survival analyses of OS and DFS in patients with ESCC

Age (y)

0.613

0.577

 <60

1

1

 ≥60

1.064 (0.836–1.355)

0.938 (0.748–1.176)

Gender

0.071

0.293

 Male

1

1

 Female

0.736 (0.528–1.026)

0.852 (0.632–1.148)

Tumor length (cm)

< 0.001

0.042

< 0.001

0.069

 <3.5

1

1

1

1

 ≥3.5

1.980 (1.518–2.583)

1.345 (1.010–1.791)

1.844 (1.442–2.358)

1.276 (0.981–1.659)

Differentiation

0.982

0.305

 Well - moderate

1

1

 Poor

1.003 (0.750–1.342)

1.150 (0.880–1.502)

Depth of tumor invasion

< 0.001

< 0.001

< 0.001

< 0.001

 T1-2

1

1

1

1

 T3-4

3.005 (2.208–4.088)

2.364 (1.707–3.275)

2.446 (1.865–3.206)

1.838 (1.378–2.450)

Lymph node metastasis

< 0.001

< 0.001

< 0.001

< 0.001

 N0

1

1

1

1

 N1-3

2.450 (1.917–3.130)

2.468 (1.901–3.205)

2.355 (1.872–2.964)

2.056 (1.624–2.602)

TNM stage

< 0.001

< 0.001

 I-II

1

1

 III

3.752 (2.756–5.109)

3.264 (2.480–4.295)

Adjuvant chemotherapy

0.010

< 0.001

0.108

 No

1

1

1

 Yes

0.731 (0.575–0.928)

0.476 (0.370–0.612)

0.831 (0.663–1.042)

NLR

0.010

0.532

0.034

0.886

 <1.6

1

1

1

1

 ≥1.6

1.454 (1.095–1.931)

1.103 (0.812–1.497)

1.325 (1.021–1.720)

1.021 (0.770–1.354)

PLR

< 0.001

0.001

 <126

1

1

 ≥126

1.619 (1.275–2.058)

1.462 (1.167–1.831)

Fibrinogen (g/L)

< 0.001

0.001

 <3.8

1

1

 ≥3.8

1.655 (1.301–2.107)

1.489 (1.184–1.873)

F-PLR score

< 0.001

0.002

< 0.001

0.003

 0

1

1

1

1

 1

1.513 (1.140–2.009)

1.248 (0.931–1.673)

1.336 (1.029–1.736)

1.165 (0.888–1.529)

 2

2.327 (1.700-3.184)

1.725 (1.222–2.434)

1.967 (1.463–2.646)

1.639 (1.183–2.270)